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Abstract We previously examined the expression of Rbm5
during myoblast differentiation and found significantly more
protein in the early stages of skeletal myoblast differentiation
than during the later stages. We decided to determine if this
elevated level was necessary for differentiation. Our hypoth-
esis was that if high levels of Rbm5 protein expression were
necessary for the initiation of skeletal myoblast differentiation,
then inhibition of expression would prevent differentiation.
Our long-term objective is to inhibit Rbm5 expression and
examine the effect on H9c2 differentiation. Towards this
end, stable knockdown clones and transient knockdown pop-
ulations were generated. Expression analyses in H9c2 myo-
blasts demonstrated significant Rbm5 messenger RNA
(mRNA) inhibition but, surprisingly, no effect on RBM5 pro-
tein levels. Expression of the Rbm5 paralogue Rbm10 was
examined in order to (a) ensure no off-target knockdown ef-
fect, and (b) investigate any possible compensatory effects.
RBM10 protein levels were found to be elevated, in both the
clonal and transiently transfected populations. These results
suggest that myoblast RBM5 expression is regulated by a
process that includes RNA sequestration and/or controlled
translation, and that (a) RBM5 function is compensated for
by RBM10, and/or (b) RBM5 regulates RBM10 expression.
We have developed a model to describe our findings, and
suggest further experiments for testing its validity. Since up-
regulation of Rbm10 might compensate for downregulated
Rbm5, and consequently might mask any potential knock-
down effect, it could lead to incorrect conclusions regarding
the importance of Rbm5 for differentiation. It is therefore im-
perative to determine how both RBM5 and RBM10 protein
expression is regulated.
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Introduction
In general, the expression of RNA-binding motif domain pro-
tein 5 (RBM5) is highest in cells that have reduced prolifera-
tion such as aging cells (Geigl et al. 2004), dormant seeds
(Sugliani et al. 2010), and in adult thymus compared to fetal
liver (Drabkin et al. 1999), and lowest in highly proliferating
cells, e.g., most cancers such as non-small cell lung cancers
(Oh et al. 2002), vestibular schwannomas (Welling et al.
2002), prostate cancers (Zhao et al. 2012), stage III serious
ovarian carcinomas (Kim et al. 2010), pancreatic cancers
(Peng et al. 2013), and biliary tract cancers (Miller et al.
2009). In fact, RBM5 was shown to be one of nine genes
down regulated in metastasis as part of the 17-gene signature
associated with metastasis in various solid tumor types
(Ramaswamy et al. 2003; Qiu et al. 2004). The triggers for
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these expression fluctuations are unknown; however, using
cancer cell lines, some of the mechanisms by which RBM5
expression can be regulated have been identified. For instance,
RBM5 can be downregulated at the transcriptional level by a
process that involves the read-through of polymerase from the
upstream RBM6 gene and the consequent generation of
Btranscription-induced chimeras^ (Wang et al. 2007).
Changes in RBM5 expression also occur via the regulation
of alternative splicing, a role played by human epidermal
growth factor receptor 2 (Rintala-Maki et al. 2007) and poten-
tially, the antisense non-coding RBM5-related factor, LUST
(Rintala-Maki and Sutherland 2009). Post-transcriptionally,
RBM5 can be differentially phosphorylated (Shu et al. 2007).
Changes in RBM5 expression levels are associated with
changes in both the expression level and the alternative splic-
ing of downstream transcripts. For example, overexpression
of RBM5 in the human leukemic cell line CEM-C7 was asso-
ciated with altered expression of 35 genes, including cyclin-
dependant kinase 2 (CDK2) and signal transducer and activa-
tor of transcription 5B (Stat5b), which are involved in process-
es such as G1/S transition and apoptosis, respectively
(Mourtada-Maarabouni et al. 2006). Knockdown of RBM5
was associated with altered expression of many genes in a
number of different cell lines (a normal lung epithelial cell
line (BEAS-2B), a normal breast epithelial cell line (MCF-
10A) and three different lung cancer cell lines with varying
RBM5 expression levels (A549, Calu-6 and NCI-H1299), no-
tably increasing the expression of genes involved in cell ad-
hesion, migration, and motility, all processes important to me-
tastasis (Oh et al. 2010). In addition, in the MCF-7 breast
adenocarcinoma cell line, RBM5 and tumor necrosis factor
alpha (TNF-α) expression were shown to be positively corre-
lated, TNF-α being an important apoptosis regulatory factor
(Wang et al. 2012). RBM5 also regulates alternative splicing
of pre-messenger RNAs (mRNAs) involved in apoptosis (ex-
clusion of caspase-2 exon 9 (Fushimi et al. 2008) and FAS
receptor exon 6 (Bonnal et al. 2008)), seed maturation (the
inclusion of an ABIα/β exon (Sugliani et al. 2010), muscular
dystrophy (exclusion of dystrophin exons 40 and 72 (O’Leary
et al. 2009) and immunoglobulin diversification (exclu-
sion of activation-induced cytidine deaminase exon 4
(Jin et al. 2012).
Is it important to note that RBM5 shares highest homology
with another RBM protein, RNA-binding motif domain pro-
tein 10 (RBM10) (Sutherland et al. 2005). In fact, RBM5 and
RBM10 are approximately 50% homologous at the transcript
level in both human and rat. Also, endogenous RBM5 and
RBM10v1 protein expression levels have been shown to be
significantly positively correlated in primary breast cancer
samples (Rintala-Maki et al. 2007).
Similar to RBM5, RBM10 has been shown to influence the
alternative splicing of many genes (Behzadnia et al. 2007;
Bechara et al. 2013; Wang et al. 2013; Zheng et al. 2013;
Inoue et al. 2014). RBM10 is also important for the regulation
of apoptosis and proliferation (James et al. 2007; Wang et al.
2012). Very little is known in regards to the importance of
RBM5 and RBM10 in muscle differentiation; however, (a)
both Rbm5 and Rbm10 are downregulated in H9c2 skeletal
muscle differentiation (Loiselle and Sutherland 2014) and
highly expressed in skeletal and cardiac muscle (Drabkin et al.
1999; Johnston et al. 2010), (b) RBM5 influences the alterna-
tive splicing of dystrophin, an important muscle protein
(O’Leary et al. 2009), and (c) RBM10 is important to sperma-
tid differentiation (O’Bryan et al. 2013).
In our previous study, we identified the rat H9c2 myoblast
differentiation model as a suitable function-based muscle
model in which to study Rbm5 and Rbm10 (Loiselle and
Sutherland 2014). Our long-term objective is to determine
the importance of Rbm5 to myoblast differentiation. In the
study described herein, we manipulated Rbm5 expression
levels in undifferentiated myoblasts, in order to characterize
expression prior to differentiation. The effects of knockdown
and overexpression of Rbm5 on Rbm10 mRNA and protein
expression levels were also examined, to rule out off-target
knockdown effects and to determine if changes in Rbm5 ex-
pression effected the expression of Rbm10, prior to differen-
tiation. The interesting observations that were made have been
incorporated into a model that will be tested in future
experiments.
Materials and Methods
Cell culture. Cells were grown as previously described
(Loiselle and Sutherland 2014).
Stable knockdown. At 24 h prior to transfection, cells were
passed in 100-mm plates (Sarstedt, Montreal, Canada) and
as such that they would be approximately 35% confluent at
the time of transfection. Twenty-four hours following appro-
priate plating, 12 μl of Lipofectamine 2000 transfection re-
agent (Life Technologies, Burlington, Canada) was mixed
with 1.5 ml of Opti-MEM reduced serum media (Life
Technologies) with GlutaMAX (Life Technologies), and in-
cubated at room temperature for 5 min. The appropriate small
hairpin RNA (shRNA) construct (12 μg) was also mixed with
1.5 ml of Opti-MEM reduced serum media with GlutaMAX,
and incubated at room temperature for five minutes. Control
samples were transfected with CSHCTR001-nU6 shRNA
scrambled control (GeneCopoeia, Rockville, MD). Rbm5
knockdown samples were t ransfected with both
MSH039757-1 and MSH039757-6 Rbm5-specific shRNAs
(6 μg of each) (GeneCopoeia) (Table 1). The Rbm5-specific
shRNAswere 100%homologous to both rat andmouse Rbm5
sequence. Following, the Lipofectamine 2000 + Opti-MEM
and shRNA + Opti-MEM solutions were mixed together and
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incubated at room temperature for 35 min. The transfection
solution was then added to the normal, serum-containing me-
dia on the cells. Selection began 24 h post-transfection by
treating cells with 1 μg/ml of puromycin. Cells were then
cultured in antibiotic-containing media to select for successful
transfectants for at least 28 days following transfection and
until they filled a 100-mm plate (Sarstedt).
Transient knockdown.Twenty-four hours prior to transfection,
cells were passed to 6-well plates (Sarstedt) so as to be 40%
confluent at the time of transfection. Twenty-four hours after
appropriately plating cells, 5 μl of Lipofectamine 2000 trans-
fection reagent (Life Technologies) was added to 245 μl of
Opti-MEM reduced serum media (Life Technologies) with
GlutaMAX (Life Technologies), and incubated at room tem-
perature for 5 min. The appropriate small interfering RNA
(siRNA) or shRNA was also added to 245 μl of Opti-MEM
reduced serum media with GlutaMAX, and incubated at room
temperature for 5 min. The first transient knockdown experi-
ment was performed with siRNA. The siRNA used for the
control sample was Trilencer-27mer universal scrambled neg-
ative control siRNA duplex (OriGene, Rockville, MD). For
Rbm5 knockdown samples, custom on-target RBM5 duplex
siRNA (Dharmacon, Thermo Fisher Scientific, Ottawa,
Canada) was used (Table 1). The second and third transient
knockdown experiments were performed with shRNAs (same
constructs used for stable knockdown experiments). Thus,
control samples were transfected with the scramble control
CSHCTR001-nU6, and Rbm5 transient knockdown experi-
ments two and three were transfected with MSH039757-1
and MSH039757-6 Rbm5-specific shRNAs, respectively
(GeneCopoeia) (Table 1). siRNAs and shRNAs had a final
concentration of 10 nM when administered to cells.
Following a 5-min incubation, the Lipofectamine 2000 +
Opti-MEM and siRNA + Opti-MEM solutions were mixed
together and incubated at room temperature for 20 min.
Next, the transfection solution was added to the normal,
serum-containing media on the cells. Medium was not
changed after addition of transfection solution, and cell pellets
were collected at 72 h post-transfection.
Transient overexpression. The plasmid used for the transient
overexpression of RBM5 was pcDNA3. RBM5 (Rintala-
Maki and Sutherland 2004), with pcDNA3 empty vector as
the negative control. Note that RBM5 sequence in the vector
was human, which has approximately 80% homology with
rat. Cells were passaged such that a confluency of 35% would
be obtained on the day of the experiment. At that point, 12 μg
of the respective pcDNA3 plasmid and 18 μ l of
Lipofectamine 2000 transfection reagent (Life Technologies)
were each mixed separately with 1.5 ml of Opti-MEM re-
duced serum medium (Life Technologies) with GlutaMAX
(Life Technologies). After a 5-min incubation at room temper-
ature, the DNA +Opti-MEM and Lipofectamine 2000 + Opti-
MEM mixtures were mixed together, and incubated at room
temperature for 20 min. Following this, the transfection mix-
ture was added to the cells. Themediumwas not changed after
addition of the transfection mixture, and cell pellets were col-
lected at 72 h post-transfection.
RNA expression analysis. RNA extraction, reverse transcrip-
tion, and end-point semi-quantitative PCR were performed as
previously described (Loiselle and Sutherland 2014), except
in this case, 24 amplification cycles were used for glyceralde-
hyde 3-phosphate dehydrogenase (Gapdh), and 38 cycles for
Rbm5 and Rbm10 (Table 2).
Densitometric analysis was performed using AlphaEase
FC software (Alpha Innotec, Kasendorf, Germany). Rbm5
and Rbm10 mRNA expression values were first normalized
to the 300-bp ladder band to account for gel exposure differ-
ences between replicates, then to Gapdh, the reference gene
used. Next, the average of the normalized expression value
obtained for all technical replicates of a biological replicate
was determined. This average normalized expression value
was then expressed as a fold-change from the control sample
of that biological replicate, and averaged for the various bio-
logical replicates. This gave the final expression value that
was graphed.
Protein expression analysis. Protein samples were prepared as
previously described (Sutherland et al. 2000). Primary anti-
bodies used were mouse anti-α-tubulin (1:10,000, sc-8035,
Santa Cruz Biotechnologies Inc., Santa Cruz, CA); rabbit
anti-RBM10 (1:1000, A301-006A, Bethyl Laboratories Inc/
Cedarlane, Burlington, Canada); rabbit anti-RBM5 (1:2500,
ab85504, Abcam, Toronto, Canada); rabbit anti-RBM5
Table 1. Small interfering RNA Rbm5 knockdown oligonucleotides
Type Name Sequence Location Homology to Rbm10
shRNA CSHCTR001-nU6 Scrambled
MSH039757-1 5′ GTAGTGGAAGATATGGTTC 3′ Exon 3 (12/19) 63%
MSH039757-6 5′ GAGCGATATTCGAGAAATG 3′ Exon 4/5 (12/19) 63%
siRNA Trilencer-27mer universal scrambled negative control Scrambled
ON-TARGET RBM5 duplex siRNA 5′ GAGCGATATTCGAGAAATG 3′ Exon 4/5 (12/19) 63%
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LUCA-15UK (1:2000, non-commercially available
(Sutherland et al. 2000)); and rabbit anti-RBM5 SP1 and
SP2 (1:1000, non-commercially available (Bonnal et al.
2008)). A goat anti-mouse horseradish peroxidase (HRP)-con-
jugated secondary antibody (1:20,000, sc-2005, Santa Cruz
Biotechnologies Inc.) and a goat anti-rabbit HRP-conjugated
secondary antibody (1:10,000, sc-2004, Santa Cruz
Biotechnologies Inc.) were employed. The presence of anti-
bodies on the membrane was detected using Amersham ECL
Western Blotting Detection Reagents (GE Healthcare,
Mississauga, Canada) and Amersham Hyperfilm ECL (GE
Healthcare).
The membranes were stripped between probing with dif-
ferent primary antibodies using the following mild stripping
procedure: two 10-min washes in mild stripping buffer (1.5%
glycine, 0.1% SDS, 0.1% Tween 20, pH 2.2); two 10-min
washes in phosphate-buffered saline (1× PBS, pH 7.4, Life
Technologies); and finally, two 5-min washes with Tris-
buffered saline with Tween 20 (TBS-T). Densitometric
analysis was performed on the resulting blots using
AlphaEase FC software. The resulting RBM5 and
RBM10 expression values were first normalized to α-
tubulin, the reference gene used. Normalized expression
values were then expressed as fold-change from the
control sample for that biological replicate (control sam-
ple present on each gel), and the average of the techni-
cal replicates for each biological replicate determined.
Following, the average across biological replicates was
determined and graphed.
Results and Discussion
Rbm5mRNA knockdown has no effect on Rbm5 protein levels.
One hundred seventeen Rbm5 shRNA transfected H9c2
clones were obtained following 28 or 29 days of selection in
puromycin. All 117 clones were screened for Rbm5 mRNA
expression. Three clones (clones 87, 9, and 100) with signif-
icant inhibition of Rbm5 mRNA expression (>80%),
compared to the scrambled control, were chosen for further
analysis, along with two clones (clones 12 and 104) with no
visible knockdown (Fig. 1A). Surprisingly, Rbm5 protein
levels were not significantly inhibited in any of the Rbm5
knockdown clones (Fig. 1B, C). To rule out any possible clon-
al effect that could account for abnormal regulation of protein
expression, three transient transfections were performed. The
first transient transfection used siRNA-specific to Rbm5
sequence (but different from one of the shRNA se-
quences used) (KD1). The second and third transient
transfections used the shRNA from the stable knock-
down experiments, MSH039757-1 and MSH039757-6,
respectively. mRNA knockdowns ranged between 55%
and 70% (Fig. 2A), but, once again, there was no de-
crease in Rbm5 protein expression levels (Fig. 2B, C).
To ensure that antibody affinity was not an issue, three
different anti-RBM5 antibodies were used in the stable
knockdown analysis, and two in the transient knock-
down work (Figs. 1B and 2B).
Rbm5 knockdown correlates with increased Rbm10 protein
levels. Since rat Rbm10 has 57% homology with rat Rbm5,
to ensure no off-target effect of the theoretically Rbm5-
specific sh/siRNAs on Rbm10 expression, Rbm10 expression
was also examined in the knockdowns. Both shRNA and
siRNA sequences were chosen to limit the potential for off-
target effects on Rbm10: Rbm5 shRNA and siRNA sequences
were 19-mers with seven mismatches to rat Rbm10, meaning
they had 63% homology. In the clones, at the RNA level
(Fig. 1A), Rbm10 expression significantly decreased in
of all the clones with the most significant Rbm5 RNA
knockdown (clones 87, 9, and 100). At the protein level
(Fig. 1C), Rbm10 expression was surprising increased,
but only in the Rbm5 clones with the most significant
Rbm5 RNA knockdown. Additionally, Rbm10 protein
expression was unexpectedly decreased in clone 12,
which had shown no change in Rbm5 mRNA expres-
sion levels as a result of knockdown. In the transient
Rbm5 knockdown, Rbm10 mRNA and prote in
Table 2. Primers for end-point PCR
Gene name Accession no. Primer sequence (5′ to 3′) Amplicon length (bp) Annealing temp. (°C)
Actb NM_031144 F: TGAGCGCAAGTACTCTGTGTGGAT 129 62
R: TAGAAGCATTTGCGGTGCACGATG
Gapdh BC059110 F: ACCACAGTCCATGCCATCAC 452 58
R: TCCACCACCCTGTTGCTGTA
Rbm5 BC166477 F: ATGGGTTCAGACAAAAGAG 520 55
R: GCATTGCAATGTGCTTTCCTTGA
Rbm10 F1LWMO F: ATTGGCTCCCGTCGAACTAACAGT 916 (10v1) 63
R: ACTTCTCTCGGCGCTTGAAGTTCT 682 (10v2)
F forward primer (5′ primer), R reverse primer (3′ primer)
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expression were increased almost twofold, compared to
the scrambled control (Fig. 2A, C).
Rbm5 overexpression does not correlate with decreased
Rbm10 protein levels. Since inhibition of Rbm5 correlated
with increased expression of RBM10 in both the stable and
transient knockdowns, we sought to determine if the reverse
were true, and overexpression of Rbm5 correlated with de-
creased Rbm10 expression. Transient overexpression of
RBM5 protein from the human complementary DNA
(cDNA) sequence (which has approximately 80% homology
with rat) was confirmed with three different anti-RBM5 anti-
bodies (Fig. 3B), but Rbm10 protein expression levels
remained unchanged, compared to the scrambled control
transfectants (Fig. 3B,C).
Based on our findings, a number of conclusions can be
drawn. Firstly, only a small quantity of Rbm5 mRNA is trans-
lated. Secondly, regulation of Rbm5 protein expression in
H9c2 myoblasts has unique characteristics. Thirdly, decreased
Rbm5 mRNA levels regulate Rbm10 protein expression. In
the following sections, we discuss each of these conclusions,
and present a model that depicts them.
Only a small quantity of Rbm5 mRNA is translated.
Knockdown of Rbm5 mRNA in either stable or transient
transfections is not reflected at the protein level. Lack of a
positive correlation between Rbm5 mRNA and protein
expression in the transient transfections could possibly relate
to the fact that (a) Rbm5 protein is very stable or (b) the
mRNA was not inhibited sufficiently to have an effect.
When these transient data are combined with the lack of cor-
relation between Rbm5 mRNA and protein expression in the
stable clones, the data suggest that unchanged Rbm5 protein
expression levels was not due to (a) any possible clonal effect
in the stable clones or (b) Rbm5 protein stability. A
precedented explanation for the lack of correlation between
Rbm5mRNA and protein expression levels in the knockdown
experiments is that only a fraction of endogenous Rbm5
mRNA is actually translated into protein. The shRNA was
able to degrade up to 90% of the Rbm5 mRNA in the stable
clones, but the ∼10% that was left might be all that is normally
translated in the wild-type myoblasts.
One possible reason to account for the fact that only a small
portion of Rbm5 mRNA may be translated is that messenger
ribonucleoproteins (mRNPs) may be involved in sequestering
the majority of Rbm5 mRNA in H9c2 cells. Precedent for this
occurs inXenopus oogenesis, where 80% of maternal mRNAs
are sequestered in mRNP storage particles, and translation is
inhibited until specific time-points during early embryogene-
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Figure 1. Rbm5 and Rbm10 expression in Rbm5 shRNA stably
transfected H9c2 clones. (A) RT-PCR results for Rbm5 and Rbm10
expression in the various RBM5 knockdown (KD) clones, individually
from technical duplicates (i) and pooled (ii). Gapdh was used as reference
gene. (B) Representative raw Western blot protein expression data for
RBM5 and RBM10 using one anti-RBM10 antibody and various anti-
RBM5 antibodies (antibody name or manufacturer indicated on the right
of the blots). Precision Plus ladder (BioRad) was used, and ladder values
refer to weight in kilodalton (kDa). (C) Densitometric analysis of protein
expression in the various clones, individually (from technical duplicates
for each clone except clone 87 and 104 in regards to RBM10 expression)
(i) and pooled (ii). Results were normalized to alpha-tubulin. In the
pooled figures (Aii, Cii), BNo KD Clones and Controls^ represents
results from the scrambled control as well as clones which did not show
at least 70% knockdown of Rbm5 at the RNA level (clones 12 and 104),
whereas B5 KDClones^ represent results from those clones that did show
mRNA knockdown of Rbm5 (clones 87, 9, and 100). Values represent
mean±standard error (SE). Asterisk placed directly above a bar indicates
value is statistically different from control as determined by unpaired t test
(**indicates p<0.01).
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translated (Spirin 1966; Tafuri and Wolffe 1993). A second
precedent occurs in P19 murine embryonic carcinoma cell
differentiation, where the composition of mRNP-sequestered
mRNAs changes following exposure to differentiation-
inducing stimuli (Tenenbaum et al. 2000). Furthermore, in
satellite cells, transcripts of Myf5, an important regulator of
myogenesis, have been shown to be sequestered in mRNP
granules. Upon activation of the satellite cell, these granules
dissociate, leading to liberation of myogenic factor 5(Myf5)
transcripts and consequently higher levels ofMyf5 (Crist et al.
2012). This regulatory mechanism thus allows quiescent sat-
ellite cells to transcribe Myf5 without activating differentia-
tion. A similar mechanism could be occurring in the H9c2
cells, which would explain not only why a 90% knockdown
of Rbm5 mRNA is not reflected at the protein level, and why
the changes in Rbm5 protein levels during cardiac differenti-
ation were not positively correlated with changes in Rbm5
mRNA levels (i.e., during differentiation, it is not the total
amount of Rbm5 mRNA in the cell that is important but the
amount that is not sequestered, and thus available for transla-
tion) (Loiselle and Sutherland 2014).
In the overexpression experiments, exogenous Rbm5
mRNA was translated. If our sequestering hypothesis is cor-
rect, this result suggests that either (a) the cell could distin-
guish between exogenously and endogenously transcribed
Rbm5 transcript, or (b) there was a finite quantity of Rbm5
message that could be sequestered, a quantity that might be
regulated by levels of endogenous Rbm5 protein or Rbm10
mRNA/protein levels.
Regulation of Rbm5 protein expression in H9c2/myoblasts
has unique characteristics. Correlations between RBM5 ex-
pression at both the mRNA and protein levels have been ex-
amined in breast (Oh et al. 2002; Rintala-Maki et al. 2007),
lung (Liang et al. 2012), and pancreatic (Peng et al. 2013)
non-tumor and tumor tissue, and various cell lines including
A549 (lung adenocarcinoma) (Oh et al. 2010; Li et al. 2012),
Calu-6 (possibly lung carcinoma) (Oh et al. 2010), NCI-
H1299 (non-small cell lung carcinoma) (Oh et al. 2010),
U2OS (osteosarcoma) (Kobayashi et al. 2011), PC-3 (prostate
adenocarcinoma) (Zhao et al. 2012), BEAS-2B (immortalized
human bronchial epithelial cells) (Oh et al. 2010),
HEK293 (human embryonic kidney cells) (Fushimi et al.
2008), MCF-10A (immortalized epithelial cells derived
from human fibrocystic mammary tissue) (Oh et al.
2010), and those of various mantle cell and follicular
lymphomas (Weinkauf et al. 2007): a positive correla-
tion between mRNA and protein expression levels was
consistently observed. Only in non-tumor breast tissue
was a positive correlation between RBM5 mRNA and protein
expression not observed (Rintala-Maki et al. 2007). Therefore,




























































































































Figure 2. Rbm5 and Rbm10 expression in Rbm5 shRNA/siRNA
transiently transfected H9c2 cells. (A) RT-PCR results for Rbm5 and
Rbm10 expression in the various transient RBM5 knockdown (KD)
experiments, individually (from technical duplicates, except KD3 (one
technical replicate)) (i) and pooled (ii). Gapdhwas used as reference gene.
(B) Representative raw Western Blot protein expression data for RBM5
and RBM10 using one anti-RBM10 antibody and various anti-RBM5
antibodies (antibody name or manufacturer indicated on the right of the
blots). Precision Plus ladder (BioRad) was used, and ladder values refer to
weight in kDa. (C) Densitometric analysis of protein expression in the
various KD experiments, individually from one technical replicate (two
for KD1 expression of RBM5) (i) and pooled (ii). Results were
normalized to alpha-tubulin. Values represent mean±SE. Asterisk placed
directly above a bar indicates value is statistically different from control
as determined by unpaired t test (** indicates p<0.01).
332 LOISELLE ETAL.
Rbm5mRNA is translated, and the rest is sequestered (perhaps
in mRNPs) may be a restricted phenomenon that occurs in, for
example, particular cell types or in cells with certain growth
characteristics, including rat myoblasts.
Decreased Rbm5 mRNA levels regulate Rbm10 protein ex-
pression. It was interesting to note that, despite unchanged
levels of Rbm5 protein, Rbm10 protein levels went
up. This observation was particularly interesting in view
of the fact that Rbm10 mRNA levels significantly de-
creased in the stable knockdowns. Any potential off-
target effect of Rbm5 shRNA on Rbm10 was considered
highly unlikely once the elevated levels of Rbm10 pro-
tein were observed. The results suggest a complex reg-
ulatory mechanism linking degradation of Rbm5 mRNA
with Rbm10 protein expression. It is important to note
that another group has also recently reported that de-
creased expression of Rbm5 correlated with increased
levels of Rbm10. Their study was performed in injured
mouse brain homogenates (Jackson et al. 2015).
Model. Based on the results of the Rbm5 knockdown and
overexpression experiments, we hypothesize that the majority
of Rbm5 transcripts are sequestered, possibly in mRNPs, and
unavailable for translation. Release of sequestered Rbm5
transcripts would occur at certain points during differentiation,
as required. Therefore, this could be the post-transcriptional
mechanism regulating Rbm5 expression throughout H9c2
skeletal and cardiac differentiation suggested by our group
previously (Loiselle and Sutherland 2014).
We postulate that two things are occurring in H9c2
cells regarding RBM10. First, that RBM10 is a compo-
nent of the mRNP complexes sequestering Rbm5
mRNA in H9c2 cells (Fig. 4A), as RBM proteins have
been shown to play important roles in these structures,
as previously reviewed (Hieronymus and Silver 2004).
Secondly, that RBM10 can bind the 3′ UTR of its own
mRNA transcript and thereby increase its own stability.
The rat homologue of RBM10, S1-1, has already been
shown to bind the 3′ UTR of angiotensin II receptor
type 1 (AT1), stabilizing the message, and ultimately
decreasing transcript ion (Mueller et al . 2009).
Furthermore, previously identified RBM10 binding se-
quences are located within the Rbm10 3′ UTR (Fig. 5)
(Bechara et al. 2013). It is important to note that
Bechara et al. demonstrated that even 2/7 mismatches
from the top selected motifs still enabled good
RBM10 binding.
In our model, when Rbm5 mRNA is decreased and

































































































































Figure 3. Rbm5 and Rbm10 expression in Rbm5 transiently
overexpressed H9c2 cells. (A) RT-PCR results for Rbm5 and Rbm10
expression in the various transient RBM5 overexpression (OE)
experiments, individually from technical duplicates (i) and pooled (ii).
Gapdh was used as reference gene. (B) Representative raw Western Blot
protein expression data for RBM5 and RBM10 using one anti-RBM10
antibody and various anti-RBM5 antibodies (antibody name or
manufacturer indicated on the right of the blots). Precision Plus ladder
(BioRad) was used, and ladder values refer to weight in kDa. (C)
Densitometric analysis of protein expression in the various OE
experiments, individually from technical duplicates for RBM5 expression
and one technical replicate for RBM10 expression (i) and pooled (ii).
Results were normalized to alpha-tubulin. Values represent mean±SE.
Statistical significance was evaluated using an unpaired t test for each
sample compared to their respective control.
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protein would be released into the cell. This RBM10
would be free to bind the 3′ UTR of Rbm10 mRNA,
stabilizing the transcript (Fig. 4B). Initially, this may
lead to increased levels of Rbm10 mRNA and protein,
which is what we observed in our transient Rbm5
knockdown experiments (Fig. 2). Ultimately, however,
this stabilization may lead to decreased transcription of
Rbm10, as has been shown upon rat RBM10 stabiliza-
tion of AT-1 transcript (Mueller et al. 2009) (Fig. 4C).
As a result, lower levels of Rbm10 mRNA would be
expected. This is, in fact what we observed in our
Rbm5 stable knockdown clones (Fig. 1).
On the other hand, upon overexpression of Rbm5, we
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Figure 4. Model representing the effects of varying levels of Rbm5
mRNA on the expression of RBM5 and RBM10. Rbm5 and Rbm10
expression in H9c2 wild-type cells (A), upon transient Rbm5 knockdown
(B), upon stable Rbm5 knockdown (C), and upon transient Rbm5
overexpression (D). RBM5 protein is represented by blue clouds, with
lighter blue representing overexpressed protein, and RBM10 protein is
represented by purple ovals. Orange mRNP ovals represent complex
mRNP particles with various components. For in-depth model
description, refer to text.
Figure 5. RBM10 binding sites in the Rbm10 3′ UTR. Segments of the
top consensus motifs for RBM10 binding sites, as determined by Bechara
et al. (2013), underlined at their respective locations in the Rbm10 3′
UTR. Double underlined sequences are part of the motifs on each side.
All sequences have two mismatches compared to the top previously
identified motif, except the most 3′- motif which is a complete match.
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to all be sequestered in mRNP complexes, resulting in their
transcription, translation, and, as a result, higher levels RBM5
(Fig. 4D). Furthermore, since the mRNP complexes seques-
tering Rbm5 would not be disrupted by this overexpression,
we would expect Rbm10 mRNA and protein levels to remain
constant. As shown in Fig. 3, this is what we observed exper-
imentally; higher levels of RBM5 upon Rbm5 overexpres-
sion, but no change in Rbm10 mRNA or protein levels.
To test the validity of this model, immunoprecipita-
tion of Rck/p54 (p-body protein and mRNP complex
component) could be performed, followed by next gen-
eration sequencing of its associated RNA (RIP-Seq).
This would determine if Rbm5 is among the mRNP-
sequestered transcripts in H9c2 myoblasts. Furthermore,
RNA-binding protein purification and identification
(RaPID) could be used to determine if Rbm10 is a
component of the mRNP/Rbm5 mRNA complexes.
This would involve tagging Rbm5 mRNA, transfecting
it into H9c2 cells, purifying the tagged transcripts, then
detecting associated proteins via mass-spectrometry
(Slobodin and Gerst 2010). Direct binding of Rbm10
to i t s own t r ansc r ip t cou ld be ana lyzed v ia
electromobility shift assays (EMSAs), using tagged
Rbm10 3′ UTR probes. Knockdown and overexpression
of Rbm10 would not be useful to test this model since
it would involve directly manipulating levels of Rbm10,
which may mask any effect that protein levels have on
transcript expression.
Conclusion
The results from this work suggest that Rbm5 is post-
transcriptionally regulated in rat myoblasts. More specifically,
our results suggest that only a small portion of Rbm5 mRNA
may be translated in myoblasts, while the rest is sequestered in
the cell. Results from Rbm10 mRNA and protein expression
in Rbm5 knockdown and overexpression samples also sug-
gest that Rbm10 expression is influenced by Rbm5 and by its
own protein levels. This co-regulation has already been shown
in neuronal cells (Jackson et al. 2015), and suggests that, as in
transformed cells (Sutherland et al. 2000; Bonnal et al. 2008;
Fushimi et al. 2008; Wang et al. 2012; Inoue et al. 2014),
Rbm5 and Rbm10 may influence similar cellular processes
in myoblasts. Finally, the intricate regulation of Rbm5 protein
levels in H9c2 cells suggest a function of the utmost impor-
tance to myoblast differentiation, and perhaps, muscle devel-
opment in general.
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